Rheumatology International

, Volume 26, Issue 8, pp 712–716 | Cite as

Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus

  • A. I. Villa-Manzano
  • J. I. Gamez-Nava
  • M. Salazar-Paramo
  • I. C. Valera-Gonzalez
  • A. Garcia-Gonzalez
  • G. Garcia-Gonzalez
  • J. Morales-Romero
  • A. Lopez-Olivo
  • L. M. Galvan-Ramirez
  • R. Ruiz-Ruvalcaba
  • E. G. Cardona-Muñoz
  • L. Gonzalez-Lopez
Original Article
First Online:
Received:
Accepted:

Abstract

The purpose of this study was to assess the association between the serum levels of aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) with disease activity and damage in systemic lupus erythematosus (SLE). Thirty-three patients with SLE were compared with 31 controls. The assessment in SLE included disease activity indices (SLEDAI, MEX-SLEDAI) and damage index (SLICC/ACR). PIIINP and PICP were measured by radioimmunoassay. Compared with controls, mean levels of PIIINP were higher in SLE (2.9±1.8 vs. 1.8±1.2, P=0.006). PICP was also increased in SLE versus controls (163±94 vs. 102±62, P=0.007). PIIINP was correlated with SLICC/ACR (r=0.33, P=0.048). No correlation was observed between PICP and PIIINP with other clinical or therapeutic variables. These preliminary data suggests a role of PIIINP as a marker for chronic damage. Follow-up studies are required to evaluate its utility in predicting future damage.

Keywords

PIIINP PICP SLE SLICC/ACR damage 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Grants: The study was supported by Funding of CONACyT Mexico. Grants: 20000302009 and MICH-2003-C01-12442 and by the IMSS-FOFOI FP:0038/1219.

References

  1. 1.
    Wallace DJ, Hanahs Hahn B (2002) Dubois’ Lupus Erythematosus, 6th edn. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    Haupt MM, Moore GW, Hutchins GM (1981) The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 71:791–798PubMedCrossRefGoogle Scholar
  3. 3.
    Bulkley BH, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58:243–264PubMedCrossRefGoogle Scholar
  4. 4.
    McLaughlin J, Gladman DD, Urowitz MB, Bombardier C, Farewell VT, Cole E (1991) Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 34:1268–1273PubMedCrossRefGoogle Scholar
  5. 5.
    Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36:1328–1332PubMedGoogle Scholar
  6. 6.
    Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP, Risteli L, (1988) Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 34:715–718PubMedGoogle Scholar
  7. 7.
    Diez J, Lopez B, Gonzalez A, Querejeta R (2001) Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 16:328–335PubMedCrossRefGoogle Scholar
  8. 8.
    Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R (1979) Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 9:451–459PubMedCrossRefGoogle Scholar
  9. 9.
    Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T (2000) Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology 39:1110–1113PubMedCrossRefGoogle Scholar
  10. 10.
    Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F, Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erithematosus. Ann Rheum Dis 59:308–310PubMedCrossRefGoogle Scholar
  11. 11.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRefGoogle Scholar
  12. 12.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Committee on Prognosis Studies in SLE (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640Google Scholar
  13. 13.
    Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMedGoogle Scholar
  14. 14.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 38:363–369CrossRefGoogle Scholar
  15. 15.
    Sondergaard K, Heickendorff L, Risteli L, Risteli J, Zachariae H, Stengaard-Pedersen K, Deleuran B (1997) Increased levels of type I and III collagen and hyaluronan in scleroderma skin. Br J Dermatol 136:47–53PubMedCrossRefGoogle Scholar
  16. 16.
    Burgeson RE (1988) New collagens, new concepts. Annu Rev Cell Biol 4:551–577PubMedCrossRefGoogle Scholar
  17. 17.
    Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E (2001) Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60:619–626PubMedCrossRefGoogle Scholar
  18. 18.
    Parfitt AM, Si mon LS, Villanueva AR, Krane SM (1987) Procollagen type I carboxy-terminal extension peptide in serum as marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2:427–436PubMedCrossRefGoogle Scholar
  19. 19.
    VanDooren-Greebe RJ, Kuijpers AL, Buijs WC, Kniest PH, Corstens FH, Nagengast FM, de Boo T, Willems JL, Duller P, van de Kerkhof PC (1996) The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 134:481–487PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • A. I. Villa-Manzano
    • 1
  • J. I. Gamez-Nava
    • 1
    • 6
  • M. Salazar-Paramo
    • 1
  • I. C. Valera-Gonzalez
    • 1
  • A. Garcia-Gonzalez
    • 2
  • G. Garcia-Gonzalez
    • 3
  • J. Morales-Romero
    • 4
  • A. Lopez-Olivo
    • 4
  • L. M. Galvan-Ramirez
    • 5
  • R. Ruiz-Ruvalcaba
    • 5
  • E. G. Cardona-Muñoz
    • 5
  • L. Gonzalez-Lopez
    • 4
  1. 1.Division of Musculoskeletal, Autoinmune and Metabolic Diseases. Clinical Epidemiology Research UnitHospital de Especialidades del Centro Medico Nacional de Occidente, IMSSGuadalajaraMéxico
  2. 2.Baylor College of MedicineHoustonUSA
  3. 3.Department of Nuclear MedicineHospital de Especialidades del Centro Medico Nacional de Occidente, IMSSGuadalajaraMéxico
  4. 4.Department of Internal Medicine and RheumatologyHospital General Regional 110, IMSSGuadalajaraMéxico
  5. 5.Centro Universitario de Ciencias de la SaludUniversidad de Guadalajara, Jal.GuadalajaraMéxico
  6. 6. GuadalajaraMéxico

Personalised recommendations